Chang HY, Kelly EC, et al.
Current gut-directed therapies for irritable bowel syndrome.
Curr Treat Options Gastroenterol. 2006;9(4):314-323.
Drug Facts and Comparisons. 56th ed. St. Louis, MO: Facts and Comparisons; 2001.
Fauci AS, Braunwald E, et al.
Harrison's Principles of Internal Medicine. 14th ed. New York, NY: The McGraw-Hill Companies; 2000.
FDA's MedWatch safety alerts: March 2009. US Food and Drug Administration website. Available at:
. Published March 23, 2009. Accessed August 4, 2009.
International Foundation for Functional Gastrointestinal Disorders, Inc.
website. Available at:
. Accessed March 3, 2006.
Irritable Bowel Syndrome Self-help and Support Group
website. Available at:
. Accessed March 3, 2006.
Lexi-PALS.
Alosetron. EBSCO Health Library, Lexi-PALS website. Available at:
. Updated June 28, 2010. Accessed September 12, 2011.
Lexi-PALS.
Cisapride. EBSCO Health Library, Lexi-PALS website. Available at:
. Updated May 25, 2010. Accessed September 12, 2011.
Lexi-PALS.
Domperidone. EBSCO Health Library, Lexi-PALS website. Available at:
. Updated October 10, 2010. Accessed September 12, 2011.
Lexi-PALS.
Lubiprostone. EBSCO Health Library, Lexi-PALS website. Available at:
. Updated June 28, 2010. Accessed September 12, 2011.
Moeser A, Nighot PK, et al.
Recovery of mucosal barrier function in ischemic porcine ileum and colon is
stimulated by a novel agonist of the ClC-2 chloride channel, lubiprostone.
Am J Physiol Gastrointest Liver Physiol. 2007;292(2):G647-656.
Pimentel M, Park S, et al.
The effect of a nonabsorbed oral antibiotic (rifaximin) on the symptoms of the irritable bowel syndrome: a randomized trial.
Ann Intern Med
2006;145(8):557-563.
Spasmonal. EPG Online website. Available at:
. Updated June 2010. Accessed January 11, 2010.
9/26/2006 DynaMed's Systematic Literature Surveillance
: Mueller-Lissner S, Tytgat GN, Paulo LG, Quigley EM, Bubeck J, Peil H, et al. Placebo- and paracetamol-controlled study on the efficacy and tolerability of hyoscine butylbromide in the treatment of patients with recurrent crampy abdominal pain.
Aliment Pharmacol Ther. 2006;23(12):1741-1748.
4/10/2007 DynaMed's Systematic Literature Surveillance
: US Food and Drug Administration. FDA announces discontinued marketing of GI drug, Zelnorm, for safety reasons [press release]. March 30, 2007. US Food and Drug Administration website. Available at:
9/18/2009 DynaMed's Systematic Literature Surveillance
: Bijkerk CJ, de Wit NJ, Muris JW, Whorwell PJ, Knottnerus JA, Hoes AW. Soluble or insoluble fibre in irritable bowel syndrome in primary care? Randomised placebo controlled trial.
BMJ. 2009;339:b3154.
11/4/2009 DynaMed Systematic Literature Surveillance
: Ford AC, Brandt LJ, Young C, Chey WD, Foxx-Orenstein AE, Moayyedi P. Efficacy of 5-HT3 antagonists and 5-HT4 agonists in irritable bowel syndrome: systematic review and meta-analysis.
Am J Gastroenterol. 2009;104(7):1831-1843.
1/11/2010 DynaMed's Systematic Literature Surveillance
: Wittmann T, Paradowski L, Ducrotté P, Bueno L, Andro Delestrain MC. Clinical trial: efficacy of alverine citrate/simethicone combination on abdominal pain/discomfort in irritable bowel syndrome: results of a randomized, double-blind, placebo-controlled study.
Aliment Pharmacol Ther. 2009 Dec 10. [Epub ahead of print]
4/30/2010 DynaMed's Systematic Literature Surveillance
: Moayyedi P, Ford AC, Talley NJ, Cremonini F, Foxx-Orenstein AE, Brandt LJ, Quigley EM. The efficacy of probiotics in the treatment of irritable bowel syndrome: a systematic review.
Gut. 2010;59(3):325-332.
2/18/2011 DynaMed's Systematic Literature Surveillance
: Serretti A, Mandelli L. Antidepressants and body weight: a comprehensive review and meta-analysis. J Clin Psychiatry
2010;71(10):1259-1272.
Please be aware that this information is provided to supplement the care provided by your physician. It is neither intended nor implied to be a substitute for professional medical advice. CALL YOUR HEALTHCARE PROVIDER IMMEDIATELY IF YOU THINK YOU MAY HAVE A MEDICAL EMERGENCY. Always seek the advice of your physician or other qualified health provider prior to starting any new treatment or with any questions you may have regarding a medical condition.